טוען...
Poly-ADP-ribose Polymerase Inhibitor Use in Ovarian Cancer: Expanding Indications and Novel Combination Strategies
The use of poly(ADP-ribose) polymerase inhibition (PARPi) is transforming the current standard of care for the treatment of ovarian cancer, with three different PARP inhibitors gaining U.S Food and Drug Administration (FDA) approval since 2014. Given the rapidly expanding use of PARP inhibitors, thi...
שמור ב:
| הוצא לאור ב: | Int J Gynecol Cancer |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8263126/ https://ncbi.nlm.nih.gov/pubmed/31118216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ijgc-2019-000499 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|